Matthew E. Korenberg

Matthew E. Korenberg

DirectoratLigand Pharmaceuticals· In proxies 2021–2025

Pay in FY2024+267% from the year before · Ligand Pharmaceuticals stock +50.0% the same year

Matthew E. Korenberg was paid $13.2M in FY2024 (Dec), up 267%. Ligand Pharmaceuticals stock rose 50.0% that year.

Pay$100 in the stock at the end of FY20 → $108
Pay is from the Summary Compensation Table of each Ligand Pharmaceuticals proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Experience

  1. Lifecore Biomedical, Inc. \de\Public company · 1 yr
    • Director2025 – Present · 1 yrNo stock prices for these years
  2. Ligand PharmaceuticalsPublic company · 5 yr
    • Former President and Chief Operating Officer2021 – Present · 5 yrStock in role +201%
  3. Primrose Bio, Inc.Public company · 3 yr
    • Director2023 – Present · 3 yrNo stock prices for these years
  4. Qualigen Therapeutics, Inc.Public company · 4 yr
    • Director2020 – 2024 · 4 yrNo stock prices for these years

Roles come from the proxy statements of each company.

Activity

For the press:Download CSVDownload PNGHow to use our data

Two people shown as one, or a wrong number?